Diffusion Pharmaceuticals Inc. (DFFN)
$9.25
$0.58
(6.69%)
As on 18-Oct-2023 09:30EDT
Market cap
$9 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-3 Mln
-
ROE
-0.6 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
1.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-4104.2
-
Face value
--
-
Shares outstanding
2,040,290
10 Years Aggregate
CFO
$-106.57 Mln
EBITDA
$-105.05 Mln
Net Profit
$-143.70 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Diffusion Pharmaceuticals (DFFN)
| 21.9 | 73.5 | 105.5 | 11.2 | -47.3 | -53.8 | -59.2 |
|
BSE Sensex*
| -10.8 | -0.6 | -1.7 | -8.5 | 6.4 | 7.6 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
Diffusion Pharmaceuticals (DFFN)
| -61.0 | 72.6 | -76.8 | -88.6 | -47.8 | -77.4 | -69.7 |
|
S&P Small-Cap 600
| 25.3 | 9.6 | 20.9 | -9.7 | 11.7 | 24.7 | -3.4 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Diffusion Pharmaceuticals (DFFN)
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to... tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia. Read more
-
Pres, CEO & Director
Dr. Robert J. Cobuzzi Jr., Ph.D.
-
Pres, CEO & Director
Dr. Robert J. Cobuzzi Jr., Ph.D.
-
Headquarters
Charlottesville, VA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Diffusion Pharmaceuticals (DFFN)
What is the current share price of Diffusion Pharmaceuticals Inc (DFFN) Today?
The share price of Diffusion Pharmaceuticals Inc (DFFN) is $9.25 (NASDAQ) as of 18-Oct-2023 09:30 EDT. Diffusion Pharmaceuticals Inc (DFFN) has given a return of -47.32% in the last 3 years.
What is the current PB & PE ratio of Diffusion Pharmaceuticals Inc (DFFN)?
Since, TTM earnings of Diffusion Pharmaceuticals Inc (DFFN) is negative, P/E ratio is not available.
The P/B ratio of Diffusion Pharmaceuticals Inc (DFFN) is 0.51 times as on 18-Oct-2023, a 87 discount to its peers’ median range of 4.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.68
|
0.51
|
|
2021
|
-0.03
|
0.02
|
|
2020
|
-0.07
|
0.04
|
|
2019
|
-0.03
|
0.02
|
|
2018
|
-0.01
|
0.01
|
What is the 52 Week High and Low of Diffusion Pharmaceuticals Inc (DFFN)?
The 52-week high and low of Diffusion Pharmaceuticals Inc (DFFN) are Rs -- and Rs -- as of 13-Jun-2026.
What is the market cap of Diffusion Pharmaceuticals Inc (DFFN)?
Diffusion Pharmaceuticals Inc (DFFN) has a market capitalisation of $ 9 Mln as on 18-Oct-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in Diffusion Pharmaceuticals Inc (DFFN)?
Before investing in Diffusion Pharmaceuticals Inc (DFFN), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.